Data as of Mar 14
| -0.16 / -0.35%|
The 26 analysts offering 12-month price forecasts for Novo Nordisk A/S have a median target of 47.32, with a high estimate of 60.73 and a low estimate of 31.45. The median estimate represents a +3.89% increase from the last price of 45.55.
The current consensus among 30 polled investment analysts is to Buy stock in Novo Nordisk A/S. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.